Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)
A phase 2 trial of Durvalumab, Olaparib, Paclitaxel / nab-paclitaxel in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
Overview
Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) is a phase 2 interventional study registered as NCT03775486 by AstraZeneca, with 401 participants enrolled, started 2018-12-21 and due to reach its primary completion in 2021-01-11. Interventions recorded: Durvalumab, Placebo for Olaparib, Olaparib, Nab-paclitaxel+carboplatin, Gemcitabine+carboplatin. Conditions listed: Non-small Cell Lung Cancer NSCLC. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
Shares Pemetrexed, Durvalumab, Gemcitabine, Paclitaxel / nab-paclitaxel.
- TrialIPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
Shares Pemetrexed, Durvalumab, Paclitaxel / nab-paclitaxel, Carboplatin.
- TrialStudy of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
Shares Durvalumab, Gemcitabine, Paclitaxel / nab-paclitaxel, AstraZeneca.
- TrialA Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, AstraZeneca, Carboplatin.
- TrialVolrustomig Priming Regimens Exploratory Phase II Platform Study
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, AstraZeneca, Carboplatin.
- TrialStudy of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)
Shares Pemetrexed, Durvalumab, Gemcitabine, AstraZeneca.
- TrialA Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, AstraZeneca, Carboplatin.
- TrialStudy to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitax
Shares Olaparib, Paclitaxel / nab-paclitaxel, AstraZeneca, Carboplatin.